Form 4: Director Walter Moos Acquires Rigel Pharmaceuticals Shares

Director Walter Moos acquired 5,750 shares of Rigel Pharmaceuticals common stock via a restricted stock unit vesting.

Summary

• Director Walter H. Moos acquired 5,750 shares of Rigel Pharmaceuticals (RIGL) common stock.
• The acquisition resulted from the vesting of a Restricted Stock Unit (RSU) award.
• The transaction occurred on May 15, 2026.
• Following this transaction, the director's total beneficial ownership is 18,472 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine equity grant vesting for a board member rather than an open-market purchase.

Positives

• Director increased equity stake in the company, signaling alignment with shareholder interests.

Negatives

• None identified.

Risks

• Vesting of the RSU is subject to the director's continuous service on the Board of Directors.

Future Outlook

The restricted stock units vest fully on the date prior to the company's next Annual Meeting, contingent upon continued board service.

Industry Context

StockSavvy.ai notes that director equity acquisitions via RSU vesting are standard corporate governance practices in the biotechnology sector, typically reflecting routine compensation rather than market-driven trading activity.

Comparison to Industry Standards

• The transaction is consistent with standard director compensation packages for mid-cap biotechnology firms.
• The acquisition method aligns with typical equity incentive plans used by peers such as Exelixis or Geron Corporation.

Stakeholder Impact

• Shareholders may view the increased director ownership as a positive sign of long-term commitment to the company.

Next Steps

• The director will continue to serve on the Board of Directors to satisfy the vesting requirements for future equity awards.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Insider Trading, Form 4, Director Ownership, Restricted Stock Units